Microneedle Drug Delivery Systems Market Forecasts to 2030 - Global Analysis By Component, Type, Material, Application, End User and By Geography

According to Stratistics MRC, the Global Microneedle Drug Delivery Systems Market is accounted for $5.89 billion in 2023 and is expected to reach $11.04 billion by 2030 growing at a CAGR of 9.4% during the forecast period. The devices for the regulated and effective transdermal delivery of medications, vaccines, and other therapeutic agents is known as the microneedle drug delivery systems market. The goal of microneedles, which are minimally invasive needles, is to make microchannels in the skin's outermost layer so that drugs and bioactive substances can be administered intra- or transdermally. They are used to provide painless vaccination, increasing vaccine coverage and making immunization more patient-friendly.

According to an article published by ACS, in May 2020, the researchers at the University of Pittsburgh Medical Center and the University of Pittsburgh tried to develop a microneedle array (MNA), a fingertip-sized patch with 400 microscopic needles that inject spiked protein fragments into the skin, where an immune response is most potent.

Market Dynamics:

Driver:

Enhancement of public health initiatives

With their painless and minimally intrusive drug delivery capabilities, microneedles hold enormous potential for transforming public health initiatives such as immunization campaigns. By providing a more comfortable and approachable option to traditional injections, these gadgets increase accessibility to immunization and reduce anxiety. Microneedles can promote increased vaccine acceptance and compliance by lessening the discomfort associated with needle injections, which will ultimately result in higher immunization coverage rates. Therefore, the goal of improving health outcomes and disease control is aligned with the deployment of microneedle drug delivery systems in public health programs, which is a driving force behind the development of this cutting-edge medical technology.

Restraint:

Expensive production of microneedles

These specialized gadgets need complex engineering, precise quality control, and the use of biocompatible materials in their creation and manufacturing. These elements limit the market potential by raising the cost of production. However, this cost can lead to increased prices for products that use microneedles. These expenses may restrict the adoption of the treatment by making it difficult for patients and healthcare providers to obtain care.

Opportunity:

Increasing drug absorption and bioavailability

Drug delivery is made more effective by the microchannels that are created in the skin by microneedles. Drugs can avoid the gastrointestinal system due to microneedles, which may result in a shorter duration of action and better bioavailability. This may lead to lower doses of more potent treatments that are more effective, lowering the possibility of adverse effects and enhancing patient outcomes. Furthermore, the capacity to augment drug absorption and bioavailability signifies a significant advancement in the domain of drug delivery, rendering microneedles a compelling choice for pharmaceutical corporations, healthcare professionals, and patients in search of enhanced therapeutic alternatives.

Threat:

Limited drug compatibility

Even though microneedles present a promising and user-friendly method of drug administration, not all drugs are appropriate for use with this technology. Microneedles' composition and design may limit the medications that can be used with them to those that have certain qualities, including the right molecular size, solubility, and stability. This constraint limits the types of drugs and biologics that may be delivered with microneedles in an efficient manner, which may prevent some essential drugs from benefiting from this novel delivery system. However, it can take some time and be expensive to build microneedle-based devices for particular medications.

COVID-19 Impact:

The government's lockdown methods and the hospital and clinic closures resulted in a disruption of care for people with chronic illnesses brought on by their lifestyle choices. Because of the increasing frequency of COVID-19 infections, businesses and academic institutions are concentrating more on developing fingertip-sized skin patches for pandemic medication administration. Thus, the adoption of microneedles for COVID-19 immunization affected the market's growth during the pandemic.

The coated microneedle technology segment is expected to be the largest during the forecast period

Coated microneedle technology segment is expected to hold largest share during the forecast period. With this cutting-edge technology, the surface of microneedles with biocompatible coatings can be coated for a variety of uses. These coatings can be made to improve the stability of sensitive chemicals, control the release of medications or therapeutic agents, or improve the shelf life of microneedle products. Additionally, due to the improved patient experience and efficacy, which is fueling the growth of the microneedle drug delivery systems industry.

The dermatology segment is expected to have the highest CAGR during the forecast period

Dermatology segment is estimated to witness lucrative growth. Microneedle technology is transforming dermatological treatments by providing a precise and minimally invasive way to administer drugs, skincare products, and cosmetic therapies. Furthermore, microneedle-based dermatological operations, also known as microneedling, can treat a variety of skin issues, including wrinkles, acne scars, pigmentation, and aging symptoms.

Region with largest share:

Over the course of the forecast period, North America is anticipated to hold the largest share of the market due to an increase in the prevalence of infectious, skin, and chronic diseases; a growth in the technological advancement of drug delivery systems; an increase in the adoption of highly advanced techniques and systems in the fabrication of microneedles. Additionally, to guarantee patient safety and product efficacy, the regulatory procedure involves stringent evaluations, clinical trials, and adherence to quality standards. The development and uptake of microneedle drug delivery systems in North America will continue to be influenced by government initiatives and regulations that support new and patient-friendly drug delivery technologies as well as the prioritization of public health.

Region with highest CAGR:

The Asia Pacific region is anticipated to have profitable growth during the forecast period as a result of the expanding pharmaceutical sector and the growing need for advanced drug delivery techniques. These initiatives center on improving the composition and structure of microneedles, refining drug delivery systems, and broadening the scope of uses in areas such as vaccination, dermatology, and chronic illness care. Moreover, innovation in the region is also being promoted by partnerships among government agencies and academic institutions.

Key players in the market

Some of the key players in Microneedle Drug Delivery Systems market include: 3M, 3D-Micromac AG, Becton, Dickinson and Company, Candela Corporation, Clearside Biomedical, Inc., Corium Inc., Dermaroller GmbH, Dynatrace, Genex Technologies, Georgia Institute of Technology, Innoture Medical Technology Limited, LTS Lohmann Therapie-Systeme AG, Micron Biomedical Inc., Micropoint Technologies, My Life Technologies, NanoSmart Pharmaceuticals, Inc., Nitto Denko Corporation, PreCelleon Medical Inc., Rani Therapeutics, Raphas Co. Ltd, TheraJect Inc., Transdermal Technologies, Inc., Valeritas, Inc., Vaxess Technologies, Zosano Pharma and Zydis.

Key Developments:

In August 2023, Mind Medicine, a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.

In December 2022, Emergex looks to microneedle patches with Zosano Pharma acquisition. The assets acquired include intellectual property, license agreements, and manufacturing equipment. They also include Zosano's proprietary microneedle array patch (MAP) intradermal drug delivery system, including a reusable applicator, solid coated microneedle array patch technology, product packaging, methods for formulation and microneedle coating, and specialized equipment, designed and built for clinical and commercial manufacture of the technology.

In November 2022, CGBio, a South Korean healthcare provider, launched a skin trouble care patch, CGDew Derma Regen, in its microneedle pipeline. These microneedle patches are made from a range of materials, such as silicon, titanium, stainless steel, and polymers, to improve the diffusivity of medications to the stratum corneum by forming pores on the skin that are smaller than a micron.

In October 2022, Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The assets include intellectual property, license agreements, manufacturing equipment, Zosano's proprietary microneedle array patch (MAP) intradermal drug delivery system, solid-coated microneedle array patch technology, methods for formulation and microneedle coating, and specialized equipment.

Components Covered:

• Coated Microneedle Technology
• Hollow Microneedle Technology
• Solid Microneedle Technology
• Other Components

Types Covered:

• Dissolving Microneedle Technology
• Porous Microneedles
• 3D-Printed Microneedles
• Hydrogel Microneedles
• Other Types

Materials Covered:

• Biodegradable Microneedle Materials
• Ceramics
• Metal
• Metal Alloys
• Polymer
• Silicon
• Other Materials

Applications Covered:

• Cancer Therapy
• Dermatology
• Hormone Delivery
• Insulin Delivery
• Oncology
• Pain Management
• Pediatric Medicine
• Transdermal Drug Delivery
• Vaccine Delivery
• Other Applications

End Users Covered:

• Pharmacies
• Hospitals
• Healthcare Providers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances